BCR-PCa represents a state of recurrent disease characterized by rising PSA levels post-local therapy without metastatic disease that is detectable on conventional imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), or bone scans. This evidence concerns the gene BCR and posterior cortical atrophy.